Exane BNP Paribas analyst Jeff Stent upgraded Nestle (NSRGY) to Outperform from Underperform with a price target of CHF 89, up from CHF 80. The company’s earnings “bleed” is finished and there is material upside potential to fiscal 2025 sales growth estimates, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSRGY:
- Nestle downgraded to Underperform from Hold at Jefferies
- Nestle initiated with a Buy at Goldman Sachs
- Freight Technologies selected by Nestle Mexico to provide logistics services
- Nestle upgraded to Equal Weight from Underweight at Morgan Stanley
- Nestle chairman says company will have to take action on prices, Reuters says